Naslov
DISTINCT GD3 EXPRESSION IN BREAST CANCER SUBPOPULATIONS AFTER NOVEL THIENO[2,3-B]PYRIDINE DERIVATIVE TREATMENT

Autori
Lange, Matthias Jonathan

Vrsta, podvrsta i kategorija rada
Ocjenski radovi, diplomski rad, diplomski

Fakultet
Medicinski fakultet

Mjesto
Split

Datum
16.07

Godina
2021

Stranica
47

Mentor
Čikeš Čulić, Vedrana

Ključne riječi
GD3, breast cancer, thieno pyridine
(GD3, karcinom dojke, tieno piridin)

Sažetak
Objectives: The goal of this study was to determine GD3 expression after treatment with the novel thieno[2, 3-b]pyridine derivative, by focusing on CD44+/CD24- CSCs, CD44- epithelial cells, as well as CD44+/ CD24+ hybrid cells. Methods: The MDA-MB-231 cell line was treated with 3-amino-N-(3-chloro-2- methylphenyl)-5-oxo-5, 6, 7, 8-tetrahydrothieno[2, 3- b]quinoline-2-carboxamide (compound 1). Cells were plated onto six-well plates and treated with 2 M compound 1 for 48 h. Following this, cells were stained with anti-GD3, anti-CD44 and anti-CD24 antibodies, and then analyzed via flow cytometry. The acquisition of data of triple-stained samples was done by a BD Accuri C6 cytometer (BD Biosciences) and analyzed with the FlowLogic Software. Results: Treatment of MDA-MB-231 cells with compound 1 has led to a reduction of the expression of GD3 in CD44+/CD24- CSCs, as well as CD44- epithelial cells. GD3 expression in CD44+/CD24+ hybrid cells was not significantly reduced. Conclusion: Due to its ability to reduce GD3 expression in different breast cancer subpopulations, compound 1 has a potential to be used in the treatment of triple-negative breast cancer.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

POVEZANOST RADA